The Role of Glycosphingolipids in HIV/AIDS

被引：0
|
作者：
Lingwood, Clifford A. [1 ]
Branch, Donald R. [2 ,3 ]
机构：
[1] Hosp Sick Children, Mol Struct & Funct Program, Toronto, ON M5G 1X8, Canada
[2] Univ Toronto, Dept Med, Toronto, ON M5G 2M1, Canada
[3] Canadian Blood Serv, Toronto, ON M5G 2M1, Canada
来源：
DISCOVERY MEDICINE | 2011年 / 11卷 / 59期
关键词：
HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-1; INFECTION; GLOBOTRIAOSYL CERAMIDE; ENVELOPE GLYCOPROTEIN; CHEMOKINE RECEPTORS; EPITHELIAL-CELLS; LIPID RAFTS; CONFORMATIONAL-CHANGES; VEROTOXIN BINDING; FUSION COFACTOR;
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Much remains unknown about basic aspects of HIV-1 infection and cell susceptibility. Glycosphingolipid (GSL) binding by the HIV-1 adhesin gp120 has long been implicated in the infection of non-lymphoid cells, as well as CD4(+) T cells and monocytes, the primary targets of HIV-1 infection. We have identified the P-k blood group antigen (a GSL) globotriaosylceramide (Gb(3)) as a new resistance effector against HIV-1 infection. Significantly, the alpha-galactosyltransferase (A4GALT, Gb3 synthase) responsible for the synthesis of Gb(3) is included among markers genetically linked to HIV-1 resistance. Other GSLs, including GalCer and GM3, have been implicated as facilitators of HIV infection. This review will address the role of GSLs in HIV/AIDS but focus on the role of Gb(3) as a newly described natural resistance factor for the prevention of HIV infection and examine potential therapies that would utilize soluble analogues of this unique GSL. [Discovery Medicine 11(59):303-313, April 2011]
引用
收藏
页码：303 / 313
页数：11
相关论文
共 50 条
12345